From the Journals

Fivefold Increase in Vaping During Adolescent Pregnancies


 

TOPLINE:

Among adolescent pregnancies in the United States, the prevalence of e-cigarette use during the third trimester increased from 0.8% in 2016 to 4.1% in 2021, according to research published online on December 13 in JAMA Network Open.

METHODOLOGY:

  • Researchers analyzed data from the 2016-2021 Pregnancy Risk Assessment Monitoring System.
  • They focused on 10,428 adolescents aged 10-19 years who had had a singleton birth and provided information about their use of e-cigarettes or cigarettes.

TAKEAWAY:

  • Whereas the researchers found a roughly fivefold increase in the exclusive use of e-cigarettes, the percentage of patients using only cigarettes decreased from 9.2% in 2017 to 3.2% in 2021.
  • The percentage of patients who both vaped and smoked fluctuated between 0.6% and 1.6%.
  • The rate of small-for-gestational-age (SGA) births for adolescents who did not smoke or vape (12.9%) did not differ significantly from that among adolescents who exclusively used e-cigarettes (16.8%) or those who used both cigarettes and e-cigarettes (17.6%).
  • The researchers found use of cigarettes only was associated with a significantly higher rate of SGA births: 24.6%.

IN PRACTICE:

“Exclusive e-cigarette use and dual use of cigarettes and e-cigarettes did not seem to be statistically significantly associated with SGA birth in our analysis, but this finding should be interpreted with caution given the low prevalence of use and the limited sample size,” the study authors wrote.

SOURCE:

Xiaozhong Wen, MD, PhD, with the Jacobs School of Medicine and Biomedical Sciences at the State University of New York at Buffalo, was the corresponding author of the study.

LIMITATIONS:

Participants may have underreported their use of e-cigarettes and cigarettes because of fears of social stigma. The researchers lacked information about vaping in the first and second trimesters, exposure to secondhand smoke, cannabis use, and diet.

DISCLOSURES:

The research was supported by the National Institute on Drug Abuse; the Food and Drug Administration Center for Tobacco Products; the National Heart, Lung, and Blood Institute; and the American Heart Association. A study coauthor has received grants from Pfizer and personal fees from Johnson & Johnson, the World Health Organization, and the Campaign for Tobacco-Free Kids.

A version of this article appeared on Medscape.com.

Recommended Reading

Avoid anti-HER2 cancer therapies during pregnancy
MDedge ObGyn
Underdiagnosed: Iron deficiency anemia during pregnancy
MDedge ObGyn
AHA, AAP update neonatal resuscitation guidelines
MDedge ObGyn
Autoimmune Skin Diseases Linked To Risk Of Adverse Pregnancy Outcomes
MDedge ObGyn
Answering the unknowns of taxanes for breast cancer during pregnancy
MDedge ObGyn
The clinical utility of newly approved angiogenic markers for identifying patients at risk for adverse outcomes due to preeclampsia
MDedge ObGyn
Is there a new role for metformin in the management of gestational diabetes?
MDedge ObGyn
2023 Update on minimally invasive gynecologic surgery
MDedge ObGyn
1 in 3 women have lasting health problems after giving birth: Study
MDedge ObGyn
Toward a better framework for postmarketing reproductive safety surveillance of medications
MDedge ObGyn